Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Heron Therapeutics, Inc. Stock Gained 25% Today

By George Budwell - Sep 23, 2015 at 11:52AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A positive clinical update sent Heron Therapeutics' stock higher today.

What: Shares of Heron Therapeutics (NASDAQ: HRTX), a biotechnology company developing best-in-class medicines that address major unmet medical needs, saw its shares rise by more than 25% today on heavy volume. This marked increase in Heron's share price was triggered by the release of positive top-line data for the company's experimental pain medicine, HTX-011, from a mid-stage study.

Specifically, HTX-011 reportedly met its primary endpoint of reducing post-operative pain in the first 24 hours in patients following a bunionectomy, compared to placebo. The drug was also generally well-tolerated in the study, according to the company. 

Source: Wikimedia Commons

So what: Medicines prescribed for post-operative pain raked in over $11 billion in sales in 2014. Even so, there is a serious need for new drugs that come with fewer, less severe side effects than standard opioid analgesics that are even known to significantly extend recovery times and hospital stays. Heron hopes HTX-011 can one day help to fill this huge unmet medical need, potentially putting it in the running to become a blockbuster product in the process.  

Now what: Per the press release, management stated that they are planning to advance HTX-011 in a broad based clinical program to assess the drug's ability to reduce pain across a wide diversity of surgeries.

Put simply, the drug is probably still several years away from becoming commercially available, putting the onus for short-term value creation squarely on Heron's late-stage experimental medicine Sustol that is currently under review with the U.S. Food and Drug Administration. 

Given that Heron's shares have now appreciated by almost 300% since the beginning of the year, I'm personally content to sit tight until Sustol's ongoing review is complete and the drug's initial sales are a known before buying shares. 

HRTX Chart

After all, the stock has clearly built in a huge premium based mainly on Sustol's commercial prospects, potentially limiting any further upside, especially after today's noteworthy move upwards. 


Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Heron Therapeutics, Inc. Stock Quote
Heron Therapeutics, Inc.
$3.48 (-3.33%) $0.12

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.